Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors

J Autoimmun. 2022 Nov 3;133:102926. doi: 10.1016/j.jaut.2022.102926. Online ahead of print.ABSTRACTAlopecia Areata (AA) is a T-cell mediated autoimmune attack on hair follicles resulting in rapidly developing areas of hair loss involving the scalp and beard that can progress to total scalp hair loss (alopecia totalis) and loss of eyebrows, eyelashes, and total body hair (alopecia universalis). Affected patients have high rates of psychological disorders and decreased quality of life. There are no FDA approved treatments, and the available treatments have a high failure rate. JAK inhibitors are remarkably effective in many autoimmune diseases including Alopecia Areata. Presented is a case report of successful treatment with tofacitinib, and a literature review of the pathophysiology of alopecia areata, the mechanism of action of JAK inhibitors, and the JAK inhibitors in phase 2 and 3 trials.PMID:36335798 | DOI:10.1016/j.jaut.2022.102926
Source: Journal of Autoimmunity - Category: Allergy & Immunology Authors: Source Type: research